Reuters logo
BRIEF-Syndax announces results from phase 2 ENCORE 601 trial of entinostat in combination with Keytruda
2017年5月17日 / 晚上9点17分 / 5 个月内

BRIEF-Syndax announces results from phase 2 ENCORE 601 trial of entinostat in combination with Keytruda

May 17 (Reuters) - Syndax Pharmaceuticals Inc

* Syndax announces results from phase 2 ENCORE 601 trial of entinostat in combination with Keytruda (pembrolizumab) for the treatment of advanced melanoma

* 31% objective response rate for first stage of phase 2 melanoma cohort of ENCORE 601

* ENCORE 601 now enrolling expanded cohorts of melanoma and NSCLC patients progressed on or after anti-PD1 therapies Source text for Eikon: Further company coverage:

我们的标准:汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below